Global Acne Treatment Market Size Study & Forecast, by Product (Retinoids, Antibiotics, Isotretinoin, Others), by Route of Administration (Oral, Topical), by Age Group (10 to 17 Years, 18 to 44 Years, 45 to 64 Years, 65 Years & Above), by Distribution Cha

Global Acne Treatment Market Size Study & Forecast, by Product (Retinoids, Antibiotics, Isotretinoin, Others), by Route of Administration (Oral, Topical), by Age Group (10 to 17 Years, 18 to 44 Years, 45 to 64 Years, 65 Years & Above), by Distribution Channel (Hospital Pharmacies, Retail & Online Pharmacies), and Regional Analysis, 2023-2030

Global Acne Treatment Market is valued at approximately USD 10.48 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 5.1% over the forecast period 2023-2030. Acne treatment refers to a variety of methods, therapies, and products that are specilly developed to manage and alleviate the acne symptoms. Acne is a skin condition that develops when oil and dead skin cells block hair follicles. It is commonly characterized by the presence of pimples, blackheads, whiteheads, and in some cases, more severe forms such as cysts and nodules. The rising prevalence of acne among the population, rising demand for aesthetic procedures, coupled with the growing awareness about skincare and the availability of treatments are the most prominent factors that are propelling the market demand across the world. As per the National Center for Biotechnology Information (NCBI), it was estimated that the prevalence of acne affected 9.4% of the worldwide population in 2022, accordingly, which is recorded as the eighth most prevalent disease globally.

In addition, the growing clinical approval of drugs is exhibiting a positive influence on market growth. Clinical approval reflects the ongoing efforts in the pharmaceutical and dermatological industries to develop effective and safe solutions for managing this common skin condition. For instance, Alembic Pharmaceuticals' topical retinoid adapalene gel USP 0.3% has received approval from the U.S. Food and Drug Administration (FDA) to be used to treat acne vulgaris. Similarly, in June 2022, Zydus Lifesciences obtained FDA permission to commercialize Adapalene with Benzoyl Peroxide topical gel in the United States. This generic drug is used to treat acne. Moreover, the growing trend of customized treatment approaches, as well as the increase in medical tourism for dermatological procedures presents various lucrative opportunities over the forecast years. However, the side effects of acne treatments and the stringent regulatory standards are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Acne Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the growing concerns related to beauty among the population, increasing awareness regarding advanced treatments, and strong investment in R&D for the drugs used for the treatment of dermatology conditions. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing prevalence of acne, the introduction of new and improved acne treatment options, as well as surging demand for aesthetic treatments, are significantly propelling the market demand across the region.

Major market players included in this report are:
ABBVIE INC. (Ireland)
Botanix Pharmaceuticals (Australia)
GALDERMA (Switzerland)
Bausch Health Companies Inc. (U.S.)
GlaxoSmithKline Plc. (U.K.)
Bayer AG (Germany)
Johnson & Johnson Services, Inc. (U.S.)
Pfizer Inc. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Sun Pharmaceutical Industries Ltd. (India)

Recent Developments in the Market:
 In December 2022, Beiersdorf AG announced the acquisition of S-Biomedic NV, a business in Belgium to strengthen its expertise in the market.

 In September 2021, Mayne Pharma Group Limited unveiled the introduction of 10 mg, 20 mg, 30 mg, and 40 mg isotretinoin capsules. These capsules, now available in the U.S., offer a generic alternative to ABSORICA. They are specifically designed to address severe recalcitrant nodular acne, providing patients with an effective treatment option.

Global Acne Treatment Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product, Route of Administration, Age Group, Distribution Channel, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Retinoids
Antibiotics
Isotretinoin
Others

By Route of Administration:
Oral
Topical

By Age Group:
10 to 17 Years
18 to 44 Years
45 to 64 Years
65 Years & Above

By Distribution Channel:
Hospital Pharmacies
Retail & Online Pharmacies

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa


Companies Mentioned
ABBVIE INC. (Ireland)
Botanix Pharmaceuticals (Australia)
GALDERMA (Switzerland)
Bausch Health Companies Inc. (U.S.)
GlaxoSmithKline Plc. (U.K.)
Bayer AG (Germany)
Johnson & Johnson Services, Inc. (U.S.)
Pfizer Inc. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Sun Pharmaceutical Industries Ltd. (India)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more